Menstruation recovery after chemotherapy and luteinizing hormone-releasing hormone agonist plus tamoxifen therapy for premenopausal patients with breast cancer

被引：0
|
作者：
Kenichi Sakurai
Sadanori Matsuo
Katsuhisa Enomoto
Sadao Amano
Motomi Shiono
机构：
[1] Nihon University School of Medicine,Division of Breast and Endocrine Surgery, Department of Surgery
来源：
Surgery Today | 2011年 / 41卷
关键词：
Luteinizing hormone-releasing hormone agonist; Adjuvant chemotherapy; Menstruation recovery; Premenopausal patients; Breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：48 / 53
页数：5
相关论文
共 50 条
  • [1] Menstruation Recovery After Chemotherapy and Luteinizing Hormone-Releasing Hormone Agonist plus Tamoxifen Therapy for Premenopausal Patients with Breast Cancer
    Sakurai, Kenichi
    Matsuo, Sadanori
    Enomoto, Katsuhisa
    Amano, Sadao
    Shiono, Motomi
    SURGERY TODAY, 2011, 41 (01) : 48 - 53
  • [2] Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist
    Noguchi, M
    Noda, S
    Yoshida, M
    Ueda, S
    Shiraishi, T
    Itoh, K
    INTERNATIONAL JOURNAL OF UROLOGY, 2004, 11 (02) : 103 - 109
  • [3] Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer
    Tan, Sing-Huang
    Wolff, Antonio C.
    CLINICAL BREAST CANCER, 2007, 7 (06) : 455 - 464
  • [4] A luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer
    Tanaka, Kimihiro
    Tokunaga, Eriko
    Yamashita, Nami
    Taketani, Kenji
    Akiyoshi, Sayuri
    Morita, Masaru
    Maehara, Yoshihiko
    SURGERY TODAY, 2014, 44 (09) : 1678 - 1684
  • [5] A luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer
    Kimihiro Tanaka
    Eriko Tokunaga
    Nami Yamashita
    Kenji Taketani
    Sayuri Akiyoshi
    Masaru Morita
    Yoshihiko Maehara
    Surgery Today, 2014, 44 : 1678 - 1684
  • [6] Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer
    Raddin, Ryan S.
    Walko, Christine M.
    Whang, Young E.
    ANTI-CANCER DRUGS, 2011, 22 (03) : 299 - 302
  • [7] Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials
    Klijn, JGM
    Blamey, RW
    Boccardo, F
    Tominaga, T
    Duchateau, L
    Sylvester, R
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) : 343 - 353
  • [8] Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy
    Morote, Juan
    Comas, Inma
    Planas, Jacques
    Maldonado, Xavier
    Celma, Ana
    Placer, Jose
    Ferrer, Roser
    Carles, Joan
    Regis, Lucas
    CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : E491 - E496
  • [9] Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer
    Bong, Gary W.
    Clarke, Harry S., Jr.
    Hancock, Wanda C.
    Keane, Thomas E.
    UROLOGY, 2008, 71 (06) : 1177 - 1180
  • [10] Cost Savings and Luteinizing Hormone-Releasing Hormone Agonist
    Tucker, Steven
    JOURNAL OF ONCOLOGY PRACTICE, 2006, 2 (03) : 103 - 103
12345